Myeloma Forecast for 2016: What’s exciting, what’s real…and who do you trust?

As we start off 2016, there is excitement in the air. Three new drug approvals, the Black Swan Research Initiative® is moving strongly into cure trials; it seems that we have myeloma on the run! Yet the reality is that we all know friends, support group members, patients who are not doing well, whose lives are threatened by myeloma despite all that is new and wonderful.

Three early Christmas presents… but what will be the New Year’s resolutions?

November was an amazing month for the myeloma community: FDA approval for three new therapies. The very good, but challenging problem is how to integrate and use these three new agents within the recommended treatment protocols for myeloma patients.

First monoclonal antibody approved

Myeloma immune therapy emerges as a key theme at ASCO 2015

The 2015 annual meeting of the American Society of Clinical Oncology (ASCO) is almost upon us. It is being held in Chicago from May 29th to June 2nd. This year, approximately 100 abstracts will focus on myeloma. Thus, although many fewer than at the annual meetings of the American Society of Hematology (ASH), several abstracts of importance to the myeloma community will be presented in Chicago.